Quote this publication Share Print

MOVENTIG (naloxegol), peripheral opioid receptor antagonist laxative

GASTROENTEROLOGY - New medicinal product
Opinions on drugs - Posted on Mar 14 2016

Reason for request

Inclusion

No clinical benefit demonstrated in the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxatives. 

 

  • MOVENTIG has Marketing Authorisation in the treatment of opioid-induced constipation in adults who have had an inadequate response to laxatives.
  • After 12 weeks of treatment, the effect size in favour of naloxegol 12.5 mg/day and 25 mg/day was modest versus placebo and the efficacy at the daily dose of 12.5 mg/day was poorly established in patients with non-cancer pain.
  • Efficacy and safety have not been assessed in patients with cancer pain.

 


Clinical Benefit

Low

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments